HIV peripheral neuropathy: Pathophysiology and clinical implications

AACN Advanced Critical Care

Volumn 17, Issue 1, 2006, Pages 30-36

  Dorsey, Susan G ^a   Morton, Patricia Gonce ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF NURSING   (United States)

Author keywords

Antiretroviral drug induced toxic neuropathy; Distal sensory polyneuropathy; HIV peripheral neuropathy; Nucleoside neuropathy

Indexed keywords

ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ANAMNESIS; DAILY LIFE ACTIVITY; EFFERENT NERVE; ELECTROMYOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALNUTRITION; PAIN; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; RELAXATION TRAINING; REVIEW; RISK FACTOR; SENSORY NERVE; VIROLOGY; WALKING DIFFICULTY;

ACTIVITIES OF DAILY LIVING; AFFERENT PATHWAYS; ANALGESICS; ANTI-ARRHYTHMIA AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; EFFERENT PATHWAYS; ELECTROMYOGRAPHY; HIV INFECTIONS; HUMANS; MALNUTRITION; MEDICAL HISTORY TAKING; MOBILITY LIMITATION; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSICAL EXAMINATION; RELAXATION TECHNIQUES; RISK FACTORS;

EID: 33746063782     PISSN: 15597768     EISSN: 15597768     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Joint United Nations Programme on HIV/AIDSNAIDS. [Web site]. Available at: http://www.unaids.org. Accessed July 25, 2005.
2. Centers for Disease Control and Prevention. [Web site]. Available at: http://www.cdc.gov. Accessed July 25, 2005.
3. Sacktor, N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol. 2002;8(2):115-121.
4. Chesney, M. Adherence to HAART regimens. AIDS Patient Care STDS. 2003;17(4):169-177.
5. Wang C, Vlahov D, Galai N, et al. Mortality in HIV-seropositive versus-seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis. 2004;190(6):1046-1054.
6. Berger, A., Dukes, EM and Oster, G. Clinical characteristics and economic costs of patients with painful peripheral neuropathic disorders. J Pain. 2004;5:143-149.
7. Schifitto G, McDermott MP, McArthur JC. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurol. 2002;58(12):1764-1768.
8. Dal Pan GJ, McArthur JC Neuroepidemiology of HIV infection. Neurolo Clinics. 1996;14:359-382.
9. So YT, Holtzman DM, Abrams DI, Olney RK. Peripheral neuropathy associated with aquired immunodeficiency syndrome: prevalence and clinical features from a population-based survey. Archives Neurol. 1988;45:945-948.
10. Verma S, Estanislao Y, Simpson D. HIV-associated neuropathic pain: epidemiology, pathophysiology and management. CNS Drugs. 2005;19(4):325-334.
11. Tagliati M, Grinnell J, Godbold J, Simpson DM. Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings. Arch Neurol. 1999;56(1):84-89.
12. Fuller, GN. Cytomegalovirus and the peripheral nervous system in AIDS. J Acquir Immune Decif Syndr. 1992;5(Suppl 1):S33-S36.
13. Swanson B, Zeller JM, Paice JA. HIV-associated distal symmetrical polyneuropathy: clinical features and nursing management. JANAC. 1998;9(2):77-80.
14. Lopez OL, Becker JT, Dew MA, et al. Risk modifiers for peripheral sensory neuropathy in HIV infection/AIDS. Eur J Neurol. 2004;11(2);97-102.
15. Wulff, EA, Wang, AK and Simpson, DM. HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs. 2000;59:1251-1260.
16. Wesselingh, SL, Glass, J, McArthur, JC, Griffin, JW, Griffin, DE. Cytokine dysregulation in HIV-associated neurological disease. Adv Neuroimmunol. 1994;4(3):199-206.
17. Moore, RD, Wong, W-M E., Keruly, JC and McArthur, JC. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AID. 2000;14:273-278.
18. White, AJ. Mitochondrial toxicity and HIV therapy. Sex Transm Infect. 2001;77:158-173.
19. Simpson, DM. Selected peripheral neuropathies associated with human mmunodeficiency virus infection and antiretroviral therapy. J NeuroVirol. 2002;8(suppl 2):33-41.
20. McCarthy BG, Hsieh, ST, Stocks, A, Hauer, P, Macko, C, Cornblath, DR, Griffin, JW, McArthur, JC. Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurol. 1995;45(10):1848-1855.
21. Verma, A. Epidemiology and clinical features of HIV-1 associated neuropathies. J Peripher Nerv Syst. 2001;6(1):8-13.
22. Basbaum AI, Fields, HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci. 1984;7:309-338.
23. Fields HL, Basbaum, AI. Brainstem control of spinal pain-transmission neurons. Ann Rev Physiol. 1978;40:217-248.
24. Urban, MO, Gebhart, GF. Central mechanisms in pain. MedClin North Am. 1999;83(3):585-596.
25. Brinley, FJ Jr, Pardo, CA, Verma A. Human immunodeficiency virus and the peripheral nervous system workshop. Arch Neurol. 2001;58:1561-1566.
26. Renn, CL, Dorsey, SG. The physiology and processing of pain: a review. AACN Clin Issues. 2005;16(3): 277-290.
27. Woolf, CJ. Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy. Life Sci. 2004;74(21):2605-2610.
28. Woolf, CJ, Salter, MW. Neuronal plasticity: increasing the gain in pain. Science. 2000;288(5472):172-180.
29. Melzack, R., Coderre, TJ, Katz, J, Vaccarino, AL. Central neuroplasticity and pathological pain. Ann N Y Acad Sci. 2001;933:157-174.
30. Ren, K, Dubner, R. Central nervous system plasticity and persistent pain. J Orofac Pain. 1999;13(3):155-163.
31. Joseph, EK, Chen, X, Khasar, SG, Levine, JD. Novel mechanism of enhaned nociception in a model of AIDS therapy-induced painful peripheral neuropathy in the rat. Pain. 2004;107(1-2):147-158.
32. Newshan, G. Pain in human immunodeficiency virus disease. Semin Oncol Nurs. 1997;13(1):36-41.
33. Verma S, Micsa E, Estanislao L, et al. Neuromuscular complications in HIV. Curr Neurol Neurosci Rep. 2004;1:62-67.
34. Cornblath DR, McArthur JC. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurol. 1988;38(5):794-796.
35. Dalakas, MC. Peripheral neuropathy and antiviral drugs. J Peripher Nerv Syst. 2001;6:14-20.
36. Harrison MJG, McArthur JC. AIDS and Neurology. Edinburgh: Churchill Livingstone; 1995.
37. Miller RG. Neuromuscular complications of human immunodeficiency virus infection and antiretroviral therapy. West J Med. 1994;160:447-452.
38. Simpson DM, Tagliati N. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J AcquirImmune Defic Syndr Hum Retroviral. 1995;9:153-161.
39. Simpson DM, Tagliati M, Ramcharitar S. Neurologic complications of AIDS: new concepts and treatments. Mount Sinai J Med. 1994;61:484-491.
40. Breibart W, Rosenfeld BD, Passik SD, et al. The undertreatment of pain in ambulatory AIDS patients. Pain. 1996;65(2-3):243-249.
41. Mendell JR, Sahenk, Z. Painful sensory neuropathy. N Engl J Med. 2003;348:1243-1255.
42. Breitbart W, Passik S, McDonald MV, et al. Patient-related barriers to pain management in ambulatory AIDS patients. Pain. 1998;76(1-2):9-16.
43. Moyle GJ. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther. 2000;22:911-936.
44. Kieburtz K, Simpson DM, Yiannoustsos C. A randomized trial of amitriptyline and mexiletene for painful neuropathy in HIV infection: the ACTG 242 study team. Neurology.1998;51:1682-1688.
45. Shlay JC, Chaloner K, Max MB, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. JAMA. 1998;280(18):1590-1595.